Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
CAMBRIDGE, Mass., September 12, 2007 /PRNewswire/ -- Targanta Therapeutics Corporation today announced that 23 presentations will showcase its lead antibiotic candidate, oritavancin, and its antibiotic drug discovery platform at the upcoming 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place in Chicago, September 17-20, 2007.
Thomas Parr, Ph.D., Chief Scientific Officer of Targanta Therapeutics commented on the meeting: "We are very proud of the body of data being presented on behalf of Targanta at ICAAC this year-a true testament, we believe, to the efforts and expertise of our scientists and collaborators. We continue to be encouraged by the breadth of data supporting the differentiating characteristics of oritavancin and are pleased to be able to present for the first time promising data on our pre-clinical osteomyelitis program."
Throughout the meeting, multiple posters will highlight the in vitro activity of oritavancin, Targanta's investigational antibiotic for the treatment of gram-positive infections, against a wide spectrum of antibiotic susceptible and resistant gram-positive bacteria. In addition, two presentations at ICAAC will highlight Targanta's proprietary drug discovery platform, which utilizes bisphosphonate prodrugs of antibiotics to generate molecules that deliver antibiotics directly to the bone.
The following abstracts have been accepted for poster or slide presentation at ICAAC:
Date Time Number Type Author Title
Monday, 12:00- A-49 Poster Lehoux PK-PD of Oritavancin
Sept. 17 1:00PM CDT (ORI) Against
Streptococcus pneumoniae
(SP) in a Murine-Pneumonia
Infection Model
A-50 Poster McKay In vitro Post Antibiotic
Effect Studies of
Oritavancin against
Staphylococcus aureus and
Enterococci
A-51 Poster Bhavnani Use of Pharmacokinetic-
Pharmacodynamic (PK-PD)
Principles to Guide
Clinical Drug Development
for Oritavancin (ORI)
D-241 Poster Tomfohrde Newly Defined In Vitro
Quality Control Ranges for
Oritavancin Broth
Microdilution Testing and
the Effect of Variations
in Testing Conditions on
MIC Results
D-242 Poster Arhin Activity of Oritavancin
against Drug-resistant
Staphylococcus aureus in
the Presence of
Polysorbate-80
Wed., 10:00AM- B-1356 Slide Lehoux In Vivo Efficacy of a New
Sept. 19 10:15AM Osteotropic Prodrug in a
CDT Rabbit Model of Chronic
Osteomyelitis
10:15AM- B-1357 Slide Tanaka Preparation and In vitro
10:30AM Evaluation of
CDT Fluoroquinolone Prodrugs
for the Prevention and
Treatment of Osteomyelitis
Wed., 11:15AM- A-1437 Poster Van Bambeke Comparative Intracellular
Sept. 19 12:15PM Activity of 10
CDT Antistaphylococcal
Antibiotics (AABs) Against
a Stable Small Colony
Variant (SCV) of S. aureus
in a model of human THP-1
macrophages
C1-1471 Poster Arhin Mechanisms of Action of
Oritavancin in
Staphylococcus aureus
C1-1472 Poster Belley Differential Targeting of
Cell Wall Assembly Systems
by Oritavancin
C1-1473 Poster Rafai Far Cell-Wall Binding Sites of
Desleucyl (fluorophenyl)
benzylchloroeremomycin, a
Damaged Oritavancin
Analogue, in
Staphylococcus
aureus
C1-1474 Poster Wang Probing the Mechanism of
Inhibition of Bacterial
Peptidoglycan
Glycosyltransferases by
Glycopeptide Analogs
Wed., 12:15PM- E-1612 Poster Moeck In Vitro Activity Profile
Sept. 19 1:15PM of Oritavancin against a
CDT Broad Spectrum of Aerobic
and Anaerobic Bacterial
Pathogens
E-1613 Poster Grover In Vitro Activity Profile
of Oritavancin (ORI)
against Organisms
Demonstrating Key
Resistance Profiles to
Other Antimicrobial Agents
E-1614 Poster McKay In Vitro Time Kill Studies
of Oritavancin against
Drug-resistant Isolates of
Staphylococcus aureus and
Enterococci
E-1615 Poster Sahm Anti-Enterococcal Activity
Profile or Oritavancin, a
Potent Lipoglycopeptide
under Development for Use
against Gram-Positive
Infections
E-1616 Poster Draghi Anti-Streptococcal
Activity Profile of
Oritavancin, a
Potent Lipoglycopeptide
under Development for Use
against Gram-Positive
Infections
E-1617 Poster Sahm In Vitro Activity Profile
of Oritavancin against
Resistant Staphylococcal
Populations from a Recent
Surveillance Initiative
E-1618 Poster Wilcox In Vitro Susceptibility of
Genotypically Distinct
Clostridium difficile
Strains to Oritavancin
E-1619 Poster Belley Synergistic Effects of
Oritavancin Tested in
Combination with Other
Agents
E-1620 Poster Belley Pharmacokinetic
Concentrations of
Oritavancin Kill
Stationary-Phase and
Biofilm Staphylococcus
aureus in Vitro
E-1621 Poster Arhin Impact of Human Serum
Albumin on Oritavancin In
vitro Activity against
Staphylococcus aureus
E-1627a Poster Baines Activity of
Metronidazole,
Vancomycin and
Oritavancin
against Epidemic
Clostridium difficile
spores
About Oritavancin
Oritavancin is a novel semi-synthetic lipoglycopeptide antibiotic candidate with potent bactericidal (killing) activity against a broad spectrum of gram-positive bacteria. The product candidate has been tested in over 1500 patients and has completed two Phase 3 studies for the treatment of complicated skin and skin structure infection (cSSSI) in which the primary endpoints were met. Targanta believes oritavancin's properties may give it distinct advantages over currently marketed therapies and expects to submit a New Drug Application to the U.S. Food and Drug Administration in the first quarter of 2008 seeking to commercialize oritavancin for the treatment of cSSSI.
About Targanta Therapeutics
Targanta Therapeutics Corporation is a privately held biopharmaceutical company focused on developing and commercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings. The Company's pipeline includes oritavancin, a semi-synthetic lipoglycopeptide antibiotic, for which Targanta intends to seek U.S. regulatory approval in early 2008, as well as a number of antibacterial agents in pre-clinical development. The company has operations in Cambridge, MA, Indianapolis, IN, Montreal, Quebec, Canada and Toronto, Ontario, Canada. For further information about Targanta, visit the company's website at www.targanta.com.
Disclaimer
All forward-looking statements and other information included in this press release are based on information available to Targanta as of the date hereof, and Targanta assumes no obligation to update any such forward-looking statements or information. Targanta's actual results could differ materially from those described in Targanta's forward-looking statements.
CONTACT: Investors, Mark Leuchtenberger, President & Chief ExecutiveOfficer of Targanta Therapeutics Corporation, +1-617-577-9020 x222; orfinancial media, Brian Ritchie of Financial Dynamics, +1-212-850-5683, forTarganta Therapeutics; or scientific media Annie Moore of Spectrum ScienceCommunications, +1-202-955-6222 x2547, for Targanta Therapeutics
Web site: http://www.targanta.com/
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
Posted: September 2007
